Pharmacology • Lipid Disorders

Lipid-Lowering Drugs & Orlistat

Mechanisms, adverse effects, drug interactions & clinical pearls for dyslipidemia management
📋

Overview of Dyslipidemia

Core
  • Dyslipidemia refers to abnormal levels of lipids in the blood
    • Includes elevated LDL-C, elevated triglycerides, low HDL-C, or combinations
    • Major modifiable risk factor for atherosclerotic cardiovascular disease
  • Atherosclerosis is the underlying pathological process
    • Lipid deposition in arterial walls → plaque formation → luminal narrowing
    • Plaque rupture → thrombosis → myocardial infarction or stroke
  • Primary treatment goal: lower LDL-C and reduce atheroma burden
  • Statin therapy is first-line for most patients with elevated LDL-C
  • Non-statin agents are reserved for:
    • Patients intolerant to statins
    • Inadequate response to statin monotherapy
    • Specific lipid abnormalities (e.g., severe hypertriglyceridemia)
  • High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) lower LDL-C by ≥50%
⚡

Pathophysiology & Lipid Metabolism

Mechanism
  • Excess circulating LDL particles infiltrate the arterial intima
    • LDL undergoes oxidative modification
    • Oxidized LDL is taken up by macrophages via scavenger receptors
    • Macrophages become foam cells → fatty streak formation
  • Foam cell accumulation triggers an inflammatory cascade
    • Cytokine release → smooth muscle cell proliferation
    • Fibrous cap formation over a lipid-rich necrotic core
  • Plaque vulnerability depends on:
    • Cap thickness
    • Inflammatory infiltrate (macrophages, T-cells)
    • Lipid core size
  • Rupture exposes tissue factor → platelet aggregation → thrombus
  • Key lipoproteins:
    • LDL: primary atherogenic particle; transports cholesterol to peripheral tissues
    • VLDL: carries triglycerides from liver; remnant particles are atherogenic
    • HDL: mediates reverse cholesterol transport; cardioprotective
  • Elevated triglycerides are an independent risk factor for pancreatitis when markedly elevated (>1000 mg/dL)
💊

HMG-CoA Reductase Inhibitors (Statins)

First-Line
  • Prototype drugs: atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin
  • Mechanism of action:
    • Competitive inhibition of HMG-CoA reductase (rate-limiting step in cholesterol synthesis)
    • Reduced hepatic cholesterol content → upregulation of LDL receptors on hepatocytes
    • Increased LDL receptor expression → enhanced clearance of circulating LDL
    • Secondary decrease in VLDL synthesis → reduced triglyceride levels
  • Intensity classification:
    • High-intensity: atorvastatin 40–80 mg, rosuvastatin 20–40 mg (LDL reduction ≥50%)
    • Moderate-intensity: atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg (LDL reduction 30–50%)
    • Low-intensity: simvastatin 10 mg, pravastatin 10–20 mg (LDL reduction <30%)
  • Adverse effects:
    • Myalgia and myopathy: most common musculoskeletal complaint
    • Rhabdomyolysis: rare but serious; monitor creatine kinase (CK) if symptoms arise
    • Hepatotoxicity: elevated transaminases; check LFTs at baseline and as clinically indicated
    • New-onset diabetes: small increased risk with high-intensity statins
    • Hemorrhagic stroke: very rare association with high-dose statins
  • Drug interactions:
    • Gemfibrozil: increases risk of myopathy/rhabdomyolysis (avoid combination)
    • Cytochrome P450 inhibitors (e.g., clarithromycin, itraconazole, protease inhibitors): increase statin toxicity
    • Fibrates, niacin, and cyclosporine also increase myopathy risk
  • Contraindications:
    • Active liver disease or unexplained persistent transaminase elevation
    • Pregnancy and lactation
    • Hypersensitivity to any statin
HMG-CoA → ↓ Liver cholesterol → ↑ LDL receptors → ↓ LDL-C (≥50%) ↘ ↓ VLDL → ↓ TG
🧪

Bile Acid Sequestrants

Non-Statin
  • Prototype drugs: cholestyramine, colestipol, colesevelam
  • Mechanism of action:
    • Bind bile acids in the intestinal lumen, forming an insoluble complex
    • Prevent enterohepatic recirculation of bile salts
    • Liver increases bile acid synthesis from cholesterol → depletes hepatic cholesterol
    • Compensatory upregulation of LDL receptors → enhanced LDL clearance
  • Clinical use:
    • Adjunct to statins or as monotherapy in statin-intolerant patients
    • May be used in combination with ezetimibe or niacin
  • Adverse effects:
    • Gastrointestinal: bloating, constipation, nausea, dyspepsia
    • Increased VLDL and triglyceride levels (contraindicated in hypertriglyceridemia)
    • Malabsorption of fat-soluble vitamins (A, D, E, K) — monitor and supplement if needed
  • Drug interactions:
    • Bind to many orally administered drugs: warfarin, thiazide diuretics, digoxin, levothyroxine
    • Administer other drugs at least 1 hour before or 4 hours after sequestrant
  • Contraindication: hypertriglyceridemia (TG >300–400 mg/dL) — can exacerbate elevation
Bind bile salts → ↓ Enterohepatic recirculation → ↑ Bile salt synthesis → ↓ Liver cholesterol → ↑ LDL receptors → ↓ LDL
🧬

Nicotinic Acid (Niacin, Vitamin B3)

Non-Statin
  • Mechanism of action:
    • Reduces cAMP in adipose tissue → inhibits hormone-sensitive lipase
    • Decreased free fatty acid release from adipocytes
    • Reduced free fatty acid flux to the liver → decreased hepatic triglyceride and VLDL synthesis
    • Indirectly increases HDL (strongest effect of any lipid drug)
  • Clinical use:
    • Previously widely used; now limited due to lack of outcome benefit when added to statins
    • May be used in patients with isolated low HDL or statin intolerance
  • Adverse effects:
    • Flushing, pruritus, burning pain: prostaglandin-mediated vasodilation; reduce with aspirin or NSAIDs pre-dose
    • Extended-release formulations reduce flushing but increase hepatotoxicity risk
    • Hepatotoxicity: dose-dependent; monitor LFTs
    • Hyperglycemia: impairs glucose tolerance; use with caution in diabetes
    • Hyperuricemia: can precipitate gout
  • Contraindications:
    • Active liver disease or unexplained transaminase elevation
    • Active peptic ulcer disease
    • Severe hypotension
  • Niacin has not been shown to improve cardiovascular outcomes when added to statin therapy in large clinical trials
🔥

Fibrates (Gemfibrozil, Fenofibrate)

Triglyceride
  • Prototype drugs: gemfibrozil, fenofibrate, bezafibrate
  • Mechanism of action:
    • Activate peroxisome proliferator-activated receptor-alpha (PPARα) in the liver and adipose tissue
    • ↑ expression of lipoprotein lipase (LPL) → enhanced catabolism of triglyceride-rich lipoproteins
    • ↓ VLDL synthesis and secretion → ↓ triglycerides (primary effect)
    • Variable effect on LDL: often modest reduction; may increase LDL in some combined hyperlipidemias
    • ↑ HDL cholesterol (most patients)
  • Clinical use:
    • First-line for severe hypertriglyceridemia (TG >500 mg/dL) to prevent pancreatitis
    • Mixed dyslipidemia with elevated TG and low HDL
  • Adverse effects:
    • Myositis: especially when combined with statins (gemfibrozil risk > fenofibrate)
    • Gallstones: increased biliary cholesterol supersaturation
    • Hepatotoxicity: transaminase elevation
    • Fenofibrate: may increase serum creatinine (reversible, not true renal injury)
  • Drug interactions:
    • Statins: increased myopathy risk (gemfibrozil > fenofibrate)
    • Warfarin: displaces from protein binding → ↑ INR (monitor closely)
  • Contraindications:
    • Severe hepatic or renal impairment
    • Known gallbladder disease
PPARα activation → ↑ LPL expression → ↓ VLDL clearance → ↓ TG (primary) ↗ ↑ HDL
🛑

Ezetimibe

Cholesterol Absorption
  • Mechanism of action:
    • Inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border
    • Blocks dietary and biliary cholesterol absorption from the gut
    • Reduces hepatic cholesterol content → ↑ LDL receptor expression → ↓ LDL-C
    • No effect on triglyceride or HDL levels
  • Clinical use:
    • Adjunct to statin therapy for additional LDL reduction
    • Monotherapy in patients who cannot tolerate statins
    • Homozygous familial hypercholesterolemia (in combination with statins)
  • Adverse effects:
    • Generally well-tolerated
    • Mild gastrointestinal distress (diarrhea, abdominal pain)
    • Hepatotoxicity: rare; LFT elevation usually when combined with statins
    • Myopathy: very rare; risk increased when combined with statins
  • Contraindications:
    • Hypersensitivity
    • Active liver disease (when combined with statin)
  • Ezetimibe provides additional ~15–20% LDL reduction when added to statin therapy
🎯

PCSK9 Inhibitors

Monoclonal Ab
  • Prototype drugs: alirocumab, evolocumab
  • PCSK9 biology:
    • Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic protease
    • PCSK9 binds to LDL receptors on hepatocytes → targets them for lysosomal degradation
    • Inhibits receptor recycling → fewer LDL receptors on cell surface
  • Mechanism of action:
    • Monoclonal antibodies that bind and neutralize circulating PCSK9
    • Prevents PCSK9-mediated LDL receptor degradation
    • Increases LDL receptor density on hepatocytes → enhanced LDL clearance
    • Reduces LDL-C by an additional 50–60% beyond statin therapy
  • Clinical use:
    • Familial hypercholesterolemia (heterozygous and homozygous)
    • Established atherosclerotic cardiovascular disease with LDL-C not at goal on maximally tolerated statin
    • Statin-intolerant patients requiring aggressive LDL reduction
  • Adverse effects:
    • Injection site reactions (erythema, pain, swelling)
    • Hypersensitivity reactions (rash, pruritus)
    • No significant increase in myopathy or hepatotoxicity
  • Advantages:
    • Dramatic LDL reduction with minimal systemic side effects
    • Twice-monthly subcutaneous dosing (convenient)
    • Proven cardiovascular outcome benefit in large trials
PCSK9 (protease) → Binds LDL receptor → LDL receptor degraded → ↓ LDL clearance ⛔ Anti-PCSK9 Ab → ↑ LDL receptors → ↓↓ LDL-C
⚖️

Orlistat (Weight Loss Agent)

Lipase Inhibitor
  • Indication: weight loss in overweight or obese patients
  • Mechanism of action:
    • Reversible inhibitor of gastric and pancreatic lipases
    • Reduces hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides
    • ~30% of ingested fat passes through the intestine unabsorbed
    • Caloric deficit from fat malabsorption promotes weight loss
    • Minimal systemic absorption (acts locally in the gut)
  • Adverse effects (gastrointestinal):
    • Oily stools (steatorrhea)
    • Fecal urgency and increased frequency of bowel movements
    • Flatulence with oily discharge
    • Fat-soluble vitamin (A, D, E, K) malabsorption — supplement if used long-term
  • Contraindications:
    • Chronic malabsorption syndrome
    • Cholestasis
    • Pregnancy (category X in some regions)
    • Breastfeeding
  • Drug interactions:
    • Warfarin: monitor INR (vitamin K malabsorption)
    • Levothyroxine: may reduce absorption; separate dosing
    • Antiepileptic drugs: may reduce absorption
  • Clinical note:
    • Weight loss is modest (~3–5% of body weight over 1 year)
    • Most effective when combined with lifestyle modification (diet, exercise)
    • OTC and prescription formulations available
Dietary triglycerides → Orlistat ⛔ ↓ Pancreatic lipase → ↓ Fat hydrolysis → Fat excreted in stool
  • Orlistat causes gastrointestinal side effects that are dose-related and often improve with continued use
📊

Comparative Overview of Lipid-Lowering Agents

Summary
Drug Class Primary Effect Key Adverse Effect Contraindication
Statins ↓↓ LDL (≥50%) Myopathy, hepatotoxicity Active liver disease
Bile Acid Seq. ↓ LDL (modest) ↑ TG, GI distress Hypertriglyceridemia
Niacin ↓ LDL, ↑↑ HDL, ↓ TG Flushing, hepatotoxicity Active liver disease
Fibrates ↓↓ TG, ↑ HDL Myositis, gallstones Gallbladder disease
Ezetimibe ↓ LDL (15–20%) GI distress Hypersensitivity
PCSK9 Inhib. ↓↓↓ LDL (50–60%) Injection site reactions Hypersensitivity
Orlistat Weight loss (fat malabsorption) Steatorrhea, flatulence Malabsorption, cholestasis
  • Statins are the only lipid-lowering class proven to reduce cardiovascular events across multiple primary and secondary prevention trials
💎

Clinical Pearls & High-Yield Facts

Exam Focus
  • Statin initiation:
    • Check baseline LFTs and creatine kinase (CK) before starting therapy
    • Lipid panel should be rechecked 4–12 weeks after initiation or dose change
    • Monitor for muscle symptoms; asymptomatic CK elevation is common and not a reason to stop
  • Non-statin add-on therapy:
    • Ezetimibe is the preferred add-on for patients requiring further LDL reduction on maximally tolerated statin
    • PCSK9 inhibitors are second-line add-on for very high-risk patients or familial hypercholesterolemia
  • Hypertriglyceridemia management:
    • Lifestyle modification (diet, exercise, alcohol reduction) is first-line
    • Fibrates are the drug of choice for severe hypertriglyceridemia (TG >500 mg/dL)
    • Omega-3 fatty acids (prescription) are adjunctive for TG reduction
  • Drug interactions to remember:
    • Gemfibrozil + statin = ↑ myopathy risk (avoid)
    • Bile acid sequestrants bind other oral drugs — separate dosing
    • Niacin + statin = ↑ hepatotoxicity risk
  • Key monitoring parameters:
    • Statins: CK (if symptoms), LFTs, fasting lipid panel
    • Fibrates: LFTs, creatinine, CBC
    • Niacin: LFTs, fasting glucose, uric acid
    • Orlistat: fat-soluble vitamin levels with long-term use
  • Do NOT use gemfibrozil with statins due to markedly increased risk of rhabdomyolysis
Statins → LDL at goal? No → Add Ezetimibe → LDL at goal? No → Add PCSK9 inhibitor